The financial verification crisis of 77 pharmaceutical companies that lasted for 2 years has just passed, and the punishment of revoking the product listing because of commercial bribery has been convicted of serious dishonesty...
On April 12, the Zhejiang Pharmaceutical Equipment Procurement Platform issued the "Notice on the Evaluation Results of Medical Prices and Untrustworthy Levels in Recruitment and Procurement in Our Province (2021 Phase 1)".
The notice shows that it is based on the "Guiding Opinions of the National Medical Security Administration on the Price of Medicines and the Credit Evaluation System for Recruitment and Procurement." According to the "Zhejiang Pharmaceutical Price and Recruitment Credit Evaluation System" and other documents, the Provincial Pharmaceutical Equipment Purchasing Center will report the credit rating results of relevant pharmaceutical companies as follows:
The League Polypeptide Injection of Harbin Yuheng Pharmaceutical Co., Ltd. is involved in commercial bribery in Zhejiang Province. According to the provisions of the above-mentioned documents, the pharmaceutical company was rated as "serious" in Zhejiang province's pharmaceutical prices and untrustworthy levels of recruitment and procurement, and the company's online transactions involving varieties of products were suspended by the regulations.
The judgment notified by Zhejiang shows that since 2017, the defendant Ni Dongmin has contracted drug promotion business in Zhejiang from pharmaceutical companies such as Harbin Yuheng Pharmaceutical Co., Ltd., and then used Hangzhou Feite Company, Tianduan and Juhui respectively, and 39 companies. In the name of an independent enterprise in Dongtou, a drug promotion contract was signed with a pharmaceutical factory. After the defendant Ni Dongmin took the contract, he subcontracted the business to numerous medical representatives or the next subcontractor, including the defendant Lu Gang, and earned 5%~10% of the promotion fee. 5% of the invoice amount is deducted from the tax. In the end, each medical representative is responsible for the promotion of the drug business to hospitals and other drug users.
During the period from May 2017 to June 26, 2019, after defendant Lu Gang obtained the promotion fee for Lugua polypeptide injection from Harbin Yuheng Pharmaceutical Co., Ltd. from defendant Ni Dongmin, to increase sales, he promised to issue one deer per The standard of "Guarana Polypeptide" injection will be paid to the doctor at the First Affiliated Hospital of Wenzhou Medical University who prescribed the 8 yuan benefit fee, and the relevant doctor agreed. During the period, the defendant Lu Gang paid a total of more than 880,000 yuan in benefits to 40 doctors such as Liu 3, Chen 7, and other doctors (handled in another case), of which the above-mentioned doctors directly or indirectly received more than 800,000 yuan in cash from other doctors.
It is reported that Zhejiang Province has also carried out credit evaluations following procedures for other pharmaceutical companies with rebate problems, and some pharmaceutical companies have taken measures such as proactive price reductions to restore credit.
As early as August 2020, the National Medical Insurance Agency launched the construction of a medical price and credit evaluation system, and gave rebates to outstanding issues in the medical field, played a guiding and standardized role in the centralized procurement of medical products, and promoted the return of reasonable prices of medical products.
This time Zhejiang Province notified the credit evaluation results of a certain company Lugua Polypeptide Injection and suspended online transactions. This is the first governance case in the country where the credit evaluation has reached the "serious" rating, marking that the credit evaluation system has entered a new stage of substantive effects. The National Medical Insurance Bureau will organize provincial medical security departments and centralized medical procurement agencies to accelerate the implementation of the credit evaluation system across the country. At the same time, in response to the recently exposed medical companies’ excessively high sales costs and false expense accounting, and other issues that are contrary to honest operation and fair pricing, we continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote the fairness, reasonableness, and honesty of pharmaceutical companies. , Set prices based on the principle of conformity between quality and price, and resolutely safeguard the interests of the people.
To a certain extent, it is not difficult to see that the country’s recent determination to rectify the pharmaceutical industry has been very clear. Financially and in terms of compliance, it has already begun to strike hard. The National Medical Insurance Bureau also stated previously that pharmaceutical companies are often insensitive to the fines imposed on rebates. It is precisely based on this that the National Medical Insurance Bureau has set out to establish a medical price and recruitment credit evaluation system, canceling the opportunity for companies with serious circumstances to enter the procurement market and improving the effect of deterrence.
Comments
Post a Comment